Dr. Reddy’s Laboratories Announces the Launch of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, together with its subsidiaries collectively known as “Dr. Reddy’s”) immediately introduced the launch of Lansoprazole DR Orally Disintegrating Tablets, a therapeutic equal generic model of Prevacid SoluTab Delayed-Launch Orally Disintegrating Tablets, 15 mg and 30 mg, authorised by the U.S. Meals and Drug Administration (USFDA).

The Prevacid® model and generic had U.S. gross sales of roughly $87 million MAT for the newest twelve months ending in December 2020 in response to IMS Well being*.

Dr. Reddy’s Lansoprazole DR Orally Disintegrating Tablets can be found in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).

Please see the total prescribing info. https://www.drreddys.com/pi/lansoprazoledr_odtus_outsert_v_3.pdf

Prevacid® is a trademark of Takeda Prescription drugs U.S.A., Inc.

*IQVIA Nationwide Gross sales Perspective: Retail and Non-Retail MAT December 2020

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an built-in pharmaceutical firm dedicated to offering inexpensive and modern medicines for more healthy lives. Via its three companies – Pharmaceutical Companies & Energetic Substances, World Generics and Proprietary Merchandise – Dr. Reddy’s gives a portfolio of services and products together with APIs, customized pharmaceutical providers, generics, biosimilars and differentiated formulations. Our main therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, ache administration and dermatology. Dr. Reddy’s operates in markets throughout the globe. Our main markets embrace – USA, India, Russia & CIS international locations, and Europe. For extra info, go browsing to: www.drreddys.com

Disclaimer: This press launch might embrace statements of future expectations and different forward-looking statements which can be based mostly on the administration’s present views and assumptions and contain identified or unknown dangers and uncertainties that would trigger precise outcomes, efficiency or occasions to vary materially from these expressed or implied in such statements. Along with statements that are forward-looking by cause of context, the phrases “might”, “will”, “ought to”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “proceed” and related expressions determine forward-looking statements. Precise outcomes, efficiency or occasions might differ materially from these in such statements resulting from with out limitation, (i) basic financial circumstances comparable to efficiency of monetary markets, credit score defaults, forex change charges, rates of interest, persistency ranges and frequency / severity of insured loss occasions, (ii) mortality and morbidity ranges and developments, (iii) altering ranges of competitors and basic aggressive components, (iv) modifications in legal guidelines and rules and within the insurance policies of central banks and/or governments, (v) the influence of acquisitions or reorganization, together with associated integration points, and (vi) the susceptibility of our trade and the markets addressed by our, and our prospects’, services and products to financial downturns on account of pure disasters, epidemics, pandemics or different widespread sickness, together with coronavirus (or COVID-19), and (vii) different dangers and uncertainties recognized in our public filings with the Securities and Change Fee, together with these listed beneath the “Danger Elements” and “Ahead-Wanting Statements” sections of our Annual Report on Type 20-F for the yr ended March 31, 2020. The corporate assumes no obligation to replace any info contained herein.”